Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Коэнзим Q10 (убихинон) и его значение в «метаболической кардиологии» - Справочник поликлинического врача №8 (2012)
Коэнзим Q10 (убихинон) и его значение в «метаболической кардиологии»
Д.М.Аронов. Коэнзим Q10 (убихинон) и его значение в «метаболической кардиологии». Справочник поликлинического врача. 2012; 8: 26–32.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Sinatra ST. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med 2009; 15 (3): 44–52.
2. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J Nutr 2000; 130: 2343–8.
3. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Кардиология. 2004; 2: 72–81.
4. Mortensen SA. Overview of coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of «Q-symbio» – a multinational trial. Biofactors 2003; 18: 79–89.
5. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in phtysical exercise, hypertension and heart failure. Biofactors, 2003; 18(1–4): 91–100.
6. Sander S, Coleman CI, Patel AA et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12 (6): 464–72.
7. Baggio E, Gandini R et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15: 287–94.
8. Morisco C, Nappi A, Argenziano L et al. Noninvasive evaluation of cardiac hemodynamic during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Aspects Med 1994; 15; 155–63.
9. Hofman-Bang C, Rehnqvist N, Swedberg K et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail 1995; 1 (2): 101–7.
10. Langsjoen PH, Folkers K et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int Tissue React 1990; 12 (3): 163–8.
11. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18: 145–51.
12. Oda T. Recovery of the Frank-Starling mechanism by coenzyme Q10 in patients with load-induced contractility depression. Clin Investig 1993; 71: 150–4.
13. Belardinelli R, Mucaj A, Lacalaprice F et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005; 25 (1–4): 137–45.
14. Аронов Д.М., Иоселиани Д.Г., Красницкий В.Б. и др. Рандомизированное проспективное исследование лекарственного препарата Кудевита (коэнзим Q10) в лечении пациентов с ишемической болезнью сердца с сердечной недостаточностью II–III функционального класса. Cons. Med. 2012; 14 (1): 50–5.
15. Чапидзе Г.Э., Капанадзе С.Д., Долидзе Н.К. и др. Комбинированная терапия антиоксидантом коэнзимом Q10 и симвастатином больных коронарным атеросклерозом. Кардиология. 2006; 8: 11–3.
16. Garjani A, Andalib S, Biabani S et al. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol 2011; 666 (1–3): 135–41.
17. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Национальные рекомендации ВНОК. Рациональная фармакотерапия в кардиологии. 2011; Прил. 5: 45–6.
18. Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19 (6): 553–7.
19. Reinhart KM, Woods JA. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am J Health Syst Pharm 2012; 69 (4): 291–300.
20. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49 (23): 2231–7.
21. Molyneux SL, Lorkowski CM, George PM et al. Coenzyme Q10: An independent Predictor of Mortality in Chronic Heart Failure. J Am Coll Cardiol 2008; 52 (18): 1435–41.
22. McMurray JV ,Dunselman P, Wedel H et al. On behalf CORONA Study Group. Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure A Pre-Specified Substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). J Am Coll Cardiol 2010; 56: 1196–204.
23. Sharma A, Soliman GM, Al-Hajaj N et al. Design and evaluation of multifunctional nanocarriers for selective delivery of coenzyme Q10 to mitochondria. Biomacromolecules 2012; 13 (1): 239–52.
24. Swarnakar NK, Jain AK, Singh RP et al. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials 2011; 32 (28): 6860–74.
25. Piao H, Ouyang M, Xia D et al. In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals. Int J Pharm 2011; 419 (1–2): 255–9.
26. Meng X, Zu Y, Zhao X et al. Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process. Pharmazie 2012; 67 (2): 161–7.
2. Ibrahim WH, Bhagavan HN, Chopra RK, Chow CK. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J Nutr 2000; 130: 2343–8.
3. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Кардиология. 2004; 2: 72–81.
4. Mortensen SA. Overview of coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of «Q-symbio» – a multinational trial. Biofactors 2003; 18: 79–89.
5. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in phtysical exercise, hypertension and heart failure. Biofactors, 2003; 18(1–4): 91–100.
6. Sander S, Coleman CI, Patel AA et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12 (6): 464–72.
7. Baggio E, Gandini R et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15: 287–94.
8. Morisco C, Nappi A, Argenziano L et al. Noninvasive evaluation of cardiac hemodynamic during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Aspects Med 1994; 15; 155–63.
9. Hofman-Bang C, Rehnqvist N, Swedberg K et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail 1995; 1 (2): 101–7.
10. Langsjoen PH, Folkers K et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int Tissue React 1990; 12 (3): 163–8.
11. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18: 145–51.
12. Oda T. Recovery of the Frank-Starling mechanism by coenzyme Q10 in patients with load-induced contractility depression. Clin Investig 1993; 71: 150–4.
13. Belardinelli R, Mucaj A, Lacalaprice F et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005; 25 (1–4): 137–45.
14. Аронов Д.М., Иоселиани Д.Г., Красницкий В.Б. и др. Рандомизированное проспективное исследование лекарственного препарата Кудевита (коэнзим Q10) в лечении пациентов с ишемической болезнью сердца с сердечной недостаточностью II–III функционального класса. Cons. Med. 2012; 14 (1): 50–5.
15. Чапидзе Г.Э., Капанадзе С.Д., Долидзе Н.К. и др. Комбинированная терапия антиоксидантом коэнзимом Q10 и симвастатином больных коронарным атеросклерозом. Кардиология. 2006; 8: 11–3.
16. Garjani A, Andalib S, Biabani S et al. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol 2011; 666 (1–3): 135–41.
17. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Национальные рекомендации ВНОК. Рациональная фармакотерапия в кардиологии. 2011; Прил. 5: 45–6.
18. Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19 (6): 553–7.
19. Reinhart KM, Woods JA. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am J Health Syst Pharm 2012; 69 (4): 291–300.
20. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49 (23): 2231–7.
21. Molyneux SL, Lorkowski CM, George PM et al. Coenzyme Q10: An independent Predictor of Mortality in Chronic Heart Failure. J Am Coll Cardiol 2008; 52 (18): 1435–41.
22. McMurray JV ,Dunselman P, Wedel H et al. On behalf CORONA Study Group. Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure A Pre-Specified Substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). J Am Coll Cardiol 2010; 56: 1196–204.
23. Sharma A, Soliman GM, Al-Hajaj N et al. Design and evaluation of multifunctional nanocarriers for selective delivery of coenzyme Q10 to mitochondria. Biomacromolecules 2012; 13 (1): 239–52.
24. Swarnakar NK, Jain AK, Singh RP et al. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials 2011; 32 (28): 6860–74.
25. Piao H, Ouyang M, Xia D et al. In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals. Int J Pharm 2011; 419 (1–2): 255–9.
26. Meng X, Zu Y, Zhao X et al. Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process. Pharmazie 2012; 67 (2): 161–7.
Авторы
Д.М.Аронов
ФГБУ ГНИЦ профилактической медицины Росмедтехнологий, Москва
ФГБУ ГНИЦ профилактической медицины Росмедтехнологий, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.